We conducted subgroup analyses based on regions (Europe, other regions), sample sizes (≥60, <60), research scales (single - center, multi - center), research methods (prospective, retrospective), and the number of treatment lines (1Line, 2Line/Later Line, Any) to further analyze the relationship between PD - 1/PD - L1 and CTLA - 4 immune checkpoint inhibitors and the tumor response rate of patients. Here, RPL17 is linked to neoplasm.